产品
编 号：F485919
分子式：C16H19FN4O3
分子量：334.35
分子式：C16H19FN4O3
分子量：334.35
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 86393-37-5
产品详情
生物活性：
Amifloxacin (Win49375) is a synthetic antibacterial agent of the quinolone class.
体内研究：
Amifloxacin (WIN 49375) is highly active by the oral route, with 50% effective doses within two- to threefold of those obtained with parenteral medication. The effectiveness of Amifloxacin with various routes of medication is demonstrated with these experimental infections. When mice infected intraperitoneally with E. coli Vogel are medicated at 0.5-h postinfection subcutaneously, intravenously, or orally the ED50s for Amifloxacin are 0.6, 0.8, and 1.0 mg/kg, respectively. Blood radioactivity peaks at 0.5 h after oral administration of [14C]Amifloxacin mesylate to rats at 20 mg/kg and is equivalent to 7.1±0.26 μg of Amifloxacin per mL. From 0.75 to 4 h, blood radioactivity decreases rapidly from 7.0±0.25 μg/mL to 1.2±0.12 μg/mL. Between 8 and 48 h the rate of decline in blood radioactivity slows and is more complex. At 48 h, the blood radioactivity is equivalent to 0.14±0.02 μg/mL. Blood levels of radioactivity after i.v. administration of [14C]Amifloxacin mesylate to rats at 20 mg/kg decrease from 29.1±0.85 μg/mL at 1.0 min to 14.4±0.52 μg/mL at 10 min. From 0.25 to 4 h blood radioactivity decreases from 13.0±0.42 μg/mL to 0.97±0.09 μg/mL in a log-linear manner. The rate of elimination from 4 to 24 h is slower and more complex. At 24 h, blood radioactivity is equivalent to 0.12±0.01 ug/mL.
体外研究：
Amifloxacin (WIN 49375) is active in vitro against Pseudomonas aeruginosa isolates and shows moderate activity against Staphylococcus aureus, with MICs of less than or equal to 2 μg/mL.
Amifloxacin (Win49375) is a synthetic antibacterial agent of the quinolone class.
体内研究：
Amifloxacin (WIN 49375) is highly active by the oral route, with 50% effective doses within two- to threefold of those obtained with parenteral medication. The effectiveness of Amifloxacin with various routes of medication is demonstrated with these experimental infections. When mice infected intraperitoneally with E. coli Vogel are medicated at 0.5-h postinfection subcutaneously, intravenously, or orally the ED50s for Amifloxacin are 0.6, 0.8, and 1.0 mg/kg, respectively. Blood radioactivity peaks at 0.5 h after oral administration of [14C]Amifloxacin mesylate to rats at 20 mg/kg and is equivalent to 7.1±0.26 μg of Amifloxacin per mL. From 0.75 to 4 h, blood radioactivity decreases rapidly from 7.0±0.25 μg/mL to 1.2±0.12 μg/mL. Between 8 and 48 h the rate of decline in blood radioactivity slows and is more complex. At 48 h, the blood radioactivity is equivalent to 0.14±0.02 μg/mL. Blood levels of radioactivity after i.v. administration of [14C]Amifloxacin mesylate to rats at 20 mg/kg decrease from 29.1±0.85 μg/mL at 1.0 min to 14.4±0.52 μg/mL at 10 min. From 0.25 to 4 h blood radioactivity decreases from 13.0±0.42 μg/mL to 0.97±0.09 μg/mL in a log-linear manner. The rate of elimination from 4 to 24 h is slower and more complex. At 24 h, blood radioactivity is equivalent to 0.12±0.01 ug/mL.
体外研究：
Amifloxacin (WIN 49375) is active in vitro against Pseudomonas aeruginosa isolates and shows moderate activity against Staphylococcus aureus, with MICs of less than or equal to 2 μg/mL.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备